Clinical Trial Update: A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC) [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 clinical trial evaluated cabozantinib (XL184) with or without erlotinib in non-small cell lung cancer, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• cabozantinib (cabozantinib)

Snippet

Sponsor: Exelixis | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-01-13